Optimal group-sequential designs for simultaneous testing of superiority and non-inferiority

Statistics in Medicine

Volumn 29, Issue 7-8, 2010, Pages 743-759

  Öhrn, Fredrik ^a,b   Jennison, Christopher ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b University of Bath   (United Kingdom)

Author keywords

Adaptive re design; Clinical trial; Decision theory; Group sequential test; Non inferiority; Superiority

Indexed keywords

ARTICLE; CALCULATION; CLINICAL STUDY; MATHEMATICAL PARAMETERS; QUANTITATIVE STUDY; SEQUENTIAL ANALYSIS; SIMULATION;

ALGORITHMS; BIOSTATISTICS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; SAMPLE SIZE;

EID: 77949409796     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3790     Document Type: Article

References (24)

1. Morikawa T, Yoshida M. A useful testing strategy in phase III trials: combined test of superiority and test of equivalence. Journal of Biopharmaceutical Statistics 1995; 5:297-306.
2. Wang SJ, Hung HMJ, Tsong Y, Cui L. Group sequential test strategies for superiority and non-inferiority hypotheses in active controlled clinical trials. Statistics in Medicine 2001; 20:1903-1912.
3. Cui L, Hung H, Wang S. Modification of sample size in group sequential trials. Biometrics 1999; 55:853-857.
4. Shih WJ, Quan H, Li G. Two-stage adaptive strategy for superiority and non-inferiority hypotheses in active controlled clinical trials. Statistics in Medicine 2004; 23:2781-2798.
5. Koyama T, Sampson AR, Gleser LJ. A framework for two-stage adaptive procedures to simultaneously test non-inferiority and superiority. Statistics in Medicine 2005; 24:2439-2456.
6. Lai TL, Shih MC, Zhu G. Modified Haybittle-Peto group sequential designs for testing superiority and non-inferiority hypotheses in clinical trials. Statistics in Medicine 2006; 25:1149-1167.
7. Jennison C, Turnbull BW. Adaptive and nonadaptive group sequential tests. Biometrika 2006; 93:1-21.
8. Gould AL. 3-decision rules useful for assessing superiority or equivalence. Enar Biometrics Society, Memphis, TN, 1997.
9. Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials. Chapman & Hall/CRC: London, 2000.
10. Eales JD, Jennison C. An improved method for deriving optimal one-sided group sequential tests. Biometrika 1992; 79:13-24.
11. Eales JD, Jennison C. Optimal two-sided group sequential tests. Sequential Analysis 1995; 14:273-286.
12. Barber S, Jennison C. Optimal asymmetric one-sided group sequential tests. Biometrika 2002; 89:49-60.
13. Jennison C, Turnbull BW. Group sequential analysis incorporating covariate information. Journal of the American Statistical Association 1997; 92:1330-1341.
14. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70:659-663.
15. Jennison C, Turnbull BW. Efficient group sequential designs when there are several effect sizes under consideration. Statistics in Medicine 2006; 25:917-932.
16. Brannath W, Bauer P, Maurer W, Posch M. Sequential tests for noninferiority and superiority. Biometrics 2003; 59:106-114.
17. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35:549-556.
18. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977; 64:191-199.
19. Mehta CR, Tsiatis AA. Flexible sample size considerations using information-based interim monitoring. Drug Information Journal 2001; 35:1095-1112.
20. Schmitz N. Optimal Sequentially Planned Decision Procedures. Lecture Notes in Statistics, vol. 79. Springer: New York, 1993.
21. EMEA note for guidance on clinical investigation of medicinal products of diabetes mellitus. Available from: http://www.emea.europa.eu/pdfs/human/ewp/ 108000en.pdf [14 September 2009].
22. Home PD, Jones NP, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Komajda M, Curtis P. Rosiglitazone record study: glucose control outcomes at 18 months. Diabetic Medicine 2007; 24:626-634.
23. Göke B, Gausse-Nilsson I, Persson A. The effect of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes. Diabetes and Vascular Disease Research 2007; 4:204-213.
24. Jennison C, Turnbull BW. Mid-course sample size modification in clinical trials based on the observed treatment effect. Statistics in Medicine 2003; 22:971-993.